CJC Open最新文献

{"title":"A Mobile Setup for Atrial Fibrillation Catheter Ablation","authors":"William K. Chan MD, FRCPC, DRCPSC, Umjeet S. Jolly MD, FRCPC, DRCPSC","doi":"10.1016/j.cjco.2025.02.015","DOIUrl":"10.1016/j.cjco.2025.02.015","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 593-594"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Failure to Positive Result: Turning Aortic Insufficiency in Neocuspidization Procedure Into Excellent Results","authors":"Marien Lenoir MD, PhD , Loïc Mace MD, PhD , Beatrice Desnous MD, PhD , Grégoire Stolpe MD , Jean-Marc El Arid MD","doi":"10.1016/j.cjco.2025.02.013","DOIUrl":"10.1016/j.cjco.2025.02.013","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 675-677"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Dielectric Sensing Technology in Heart Failure: Correlating Lung-Fluid Volume Shifts with Postural Changes and Dyspnea Severity","authors":"Li-Kai Wang MD, MSc ,&nbsp;Yi-Ju Tsai PhD ,&nbsp;Ying-Chou Wang PhD ,&nbsp;June-Horng Lue PhD ,&nbsp;Chun-Ta Huang MD","doi":"10.1016/j.cjco.2025.03.003","DOIUrl":"10.1016/j.cjco.2025.03.003","url":null,"abstract":"<div><h3>Background</h3><div>Orthopnea, a common symptom in heart failure (HF), arises from elevated pulmonary pressures and interstitial edema due to positional shifts. Remote dielectric sensing (ReDS) offers a noninvasive method to quantify lung-fluid volume. This study evaluated ReDS system measurements in response to posture changes in HF patients, and the correlation of these measurements with dyspnea severity.</div></div><div><h3>Methods</h3><div>This prospective observational study included both healthy volunteers and HF patients. Lung-fluid volume was measured using the ReDS system, with the patients in 3 positions—sitting, supine, and supine with elevated legs. HF patients additionally reported dyspnea levels on a visual analog scale immediately before and after ReDS measurements were made.</div></div><div><h3>Results</h3><div>A total of 86 healthy volunteers and 20 HF patients were included in the study. In healthy volunteers, ReDS values modestly increased when patients changed from a sitting to a supine position (21% vs 22%; <em>P</em> &lt;0.001), and from being supine to supine with raised legs (22% vs 24%; <em>P</em> &lt;0.001). In contrast, HF patients showed significantly higher ReDS values across all positions (29%, 31%, and 34%, respectively), with more pronounced increases between positions compared to those of healthy subjects (<em>P</em> for interaction &lt; 0.001). A strong correlation was observed between ReDS system measurements and dyspnea visual analog scale scores in HF patients following posture changes (Pearson’s <em>r</em> = 0.718, <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The ReDS system effectively quantifies lung-fluid volume changes due to body-position shifts in HF patients. Its measurements correlate well with alterations in dyspnea severity, potentially offering an objective means to monitor HF symptoms. Further studies are needed to validate these findings in a larger cohort and over an extended period.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 606-613"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective","authors":"Nowell Fine MD ,&nbsp;Anique Ducharme MD ,&nbsp;Genevieve Matte MD ,&nbsp;Michelle Mezei MD ,&nbsp;Vera Bril MD ,&nbsp;Diego Delgado MD, MSc","doi":"10.1016/j.cjco.2025.03.002","DOIUrl":"10.1016/j.cjco.2025.03.002","url":null,"abstract":"<div><div>Hereditary amyloid transthyretin variant (ATTRv) amyloidosis is a rare, life-threatening disease, characterized by the deposition of aggregated transthyretin (TTR) protein in multiple organs and tissues. Diagnosis is often delayed due to its heterogeneity in presentation, which includes a wide range of cardiac and/or neurologic symptoms. Thus, awareness of ATTRv amyloidosis across multiple specialties is needed for its early diagnosis and management. This paper provides a review surrounding the diagnosis and management of mixed phenotype ATTRv amyloidosis, addressed through 3 clinical questions. This paper discusses: (i) the need for patients with ATTRv amyloidosis to be screened for mixed cardiac and neurologic phenotypes through early multidisciplinary referral; (ii) the therapeutic landscape for ATTRv amyloidosis in Canada, with emphasis on the need for prompt therapy selection and initiation, based on multidisciplinary collaboration; and (iii) how disease can be monitored pre- and post-treatment. Case studies are provided to illustrate how the available evidence impacts practice.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 614-627"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CArdiovasculaR Outcomes Based Upon EjectIon Systolic TimE in Patients With ST Elevation Myocardial Infarction (ARISE-STEMI) Study","authors":"Tyler Szun BSc ,&nbsp;Alexander Zaremba BSc ,&nbsp;Aleksander Dokollari MD, PhD ,&nbsp;Azin Khafipour MSc ,&nbsp;Hilary Bews MD, FRCPC ,&nbsp;Seth Cheung ,&nbsp;James W. Tam MD, FRCPC ,&nbsp;Shuangbo Liu MD, FRCPC ,&nbsp;Derek So MD, FRCPC ,&nbsp;Sean Van Diepen MD, FMSc ,&nbsp;Ashish H. Shah MD, MD-Research, FRCP","doi":"10.1016/j.cjco.2024.11.014","DOIUrl":"10.1016/j.cjco.2024.11.014","url":null,"abstract":"<div><h3>Background</h3><div>Despite improvements in revascularization, systems of care, and secondary prevention therapies, 30-day mortality rates in patients presenting with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains 4% to 6%. This study aims to investigate the utility of the ejection systolic time (EST) and ejection systolic period (ESP) in identifying high-risk STEMI patients.</div></div><div><h3>Methods</h3><div>In this retrospective study, consecutive patients with STEMI undergoing PPCI at a tertiary cardiac center between January 2020 and October 2021 were included. EST and ESP were calculated on the MacLab. Univariable and multivariable Cox regression analysis were used to identify risk predictors. The primary outcome was mortality at 30 days.</div></div><div><h3>Results</h3><div>Six hundred forty-one STEMI patients (mean age: 64.4 ± 13.2 years; 182/641 [28.4%] female patients) were recruited. Within 30 days of presentation, 32 patients (5.0%) died, and they were more frequently older, female, and had higher rates of previous stroke, chronic kidney disease, and dialysis use. Patients dying within 30 days had lower EST (0.20 ± 0.04 vs 0.24 ± 0.04 seconds/beat; <em>P</em> &lt; 0.0001) and ESP (17.64 ± 2.66 vs 19.29 ± 2.74 seconds/min; <em>P</em> = 0.004). After multivariable modeling, only EST was a significant predictor of early (&lt;30 days) mortality (hazard ratio 4.5, 95% confidence interval 1.7-12.1; <em>P</em> = 0.003), prolonged in-hospital stay (&gt;4 days), diuretic use, new diagnosis of heart failure, need for intubation or ventilation, and inotrope and/or vasopressor use during the index hospital admission. ESP and EST were not associated with the mortality between 30 days and 1 year.</div></div><div><h3>Conclusions</h3><div>A lower EST was associated with mortality at 30 days and in-hospital adverse outcomes. EST may serve as a useful hemodynamic marker to risk-stratify STEMI patients.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 516-524"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeated Transcatheter Valve Interventions After Surgical Mitral Valve Replacement: A 20-Year Journey Avoiding Surgical Redo","authors":"Christos Papageorgiou MD ,&nbsp;Marco B. Ancona MD ,&nbsp;Ciro Vella MD ,&nbsp;Vittorio Romano RT ,&nbsp;Luca A. Ferri MD ,&nbsp;Filippo Russo MD ,&nbsp;Barbara Bellini MD ,&nbsp;Giulia Ghizzoni MD ,&nbsp;Greca Zanda MD ,&nbsp;Domitilla Gentile MD ,&nbsp;Francesca Napoli MD ,&nbsp;Antonio Esposito MD ,&nbsp;Eustachio Agricola MD ,&nbsp;Alaide Chieffo MD ,&nbsp;Matteo Montorfano MD","doi":"10.1016/j.cjco.2025.01.020","DOIUrl":"10.1016/j.cjco.2025.01.020","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 489-492"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Socioeconomic Status Is Associated with Reduced Access to Natriuretic Peptide Testing in the Outpatient Setting: A Population-based Evaluation","authors":"Ismail R. Raslan MD, MSc ,&nbsp;Anna Chu MHSc ,&nbsp;Peter C. Austin PhD ,&nbsp;Xuesong Wang MSc ,&nbsp;David Bobrowski MD ,&nbsp;Barbara S. Doumouras MD ,&nbsp;Joseph J. Lee BSc ,&nbsp;Candace D. McNaughton MD, PhD ,&nbsp;Peter A. Kavsak PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Heather J. Ross MD, MHSc ,&nbsp;Douglas S. Lee MD, PhD","doi":"10.1016/j.cjco.2025.01.002","DOIUrl":"10.1016/j.cjco.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Tests of natriuretic peptide (NP) concentrations are guideline-recommended for diagnosis and prognostication in heart failure (HF). Although NP testing is available at some hospitals, outpatient access has been limited to those who can pay out-of-pocket. We investigated whether residents who have lower socioeconomic status have differential access to NP testing.</div></div><div><h3>Methods</h3><div>Using a case-control design, we compared patients who had NP tests with age-matched patients undergoing non-NP blood tests (January 2015-June 2020), performed in the outpatient or acute hospital setting. The association of socioeconomic status measures (eg, deprivation quintile) with receipt of NP testing was assessed using conditional logistic regression, adjusted for sex, test location, and comorbidities, and was stratified by incidence of prior HF.</div></div><div><h3>Results</h3><div>Among 96,919 patients without prior HF (median age, 72 years; 50% female) who underwent NP testing, the majority of tests (66.6%) were performed in an acute hospital setting rather than in an outpatient clinic. Residents of more-deprived neighbourhoods had a higher incidence of HF (<em>P</em> &lt; 0.001), but they were more likely to undergo NP testing in an acute care setting (odds ratio [OR] for most- vs least-deprived, 1.269; 95% confidence interval [CI], 1.104-1.216) and less likely to undergo testing as outpatients (OR, 0.807; 95% CI, 0.764-0.853 vs least-deprived; all <em>P</em> &lt; 0.001). Among 70,362 matched patients with known HF (median aged, 78 years; 45% female), outpatient NP testing was also less likely to be performed among patients living in the most-deprived neighbourhoods (OR, 0.723; 95% CI, 0.677-0.772; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Although those of lower socioeconomic status exhibit a higher risk of incident HF, they had less NP testing performed in outpatient settings, and more testing performed in resource-intense acute-care settings.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 390-401"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy-Induced Hypertension and Atherosclerotic Cardiovascular Disease Risk Score in China","authors":"Honghong He MM ,&nbsp;Junyan Sun MM ,&nbsp;Hongqiu Huo MB ,&nbsp;Yanxiu Wang MD ,&nbsp;Yuntao Wu MM ,&nbsp;Suhua Chen MB ,&nbsp;Yangyang Wang MM ,&nbsp;Xiaoming Zheng MD ,&nbsp;Haiyan Zhao MD","doi":"10.1016/j.cjco.2025.01.006","DOIUrl":"10.1016/j.cjco.2025.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy-induced hypertension (PIH) poses a significant threat to maternal health. This study aims to explore the association between PIH and the risk of atherosclerotic cardiovascular disease (ASCVD).</div></div><div><h3>Methods</h3><div>The cohort comprised 1947 pregnant women delivering a single child between 2004 and 2020 in the Kailuan study. Participants, categorized into PIH and non-PIH (NPIH) groups based on PIH history, completed questionnaires and underwent physical examinations and laboratory assessments within 2 years after delivery. Predicted ASCVD risks used the Atherosclerotic Cardiovascular Disease Risk in China (China-PAR) model, distinguishing lifetime ASCVD risk as \"low\" (&lt;32.8%) and \"high\" (≥32.8%). χ² tests and logistic regression were used to investigate the association between PIH and high lifetime risk China-PAR categories.</div></div><div><h3>Results</h3><div>Overall, 6.17% of the PIH group had high lifetime risk, compared with 0.96% in the NPIH group (χ² 29.59, <em>P</em> &lt; 0.001). After adjusting for confounders, PIH was independently associated with high-risk China-PAR categories, with the PIH group having a 5.03 times higher probability than the NPIH group (95% CI 2.20-11.51, <em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>Pregnancy-induced hypertension was associated with increased lifetime risk of ASCVD.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 435-440"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Pathway Inhibition in Patients with Atherosclerosis with or without Heart Failure: Insights from the XATOA Registry","authors":"Pishoy Gouda MB, BCh, BAO, MSc ,&nbsp;Justin A. Ezekowitz MD, MSc ,&nbsp;Alain Gay MD ,&nbsp;Kai Vogtländer MSc ,&nbsp;Victor Aboyans MD, PhD ,&nbsp;Sebastian Debus MD ,&nbsp;Keith Fox MB, ChB ,&nbsp;Uwe Zeymer MD ,&nbsp;Robert Welsh MD","doi":"10.1016/j.cjco.2025.01.013","DOIUrl":"10.1016/j.cjco.2025.01.013","url":null,"abstract":"<div><h3>Background</h3><div>Patients with atherosclerotic cardiovascular disease might benefit from dual pathway inhibition (DPI) therapy, which includes rivaroxaban and aspirin. Patients with concomitant heart failure (HF) are a subgroup with a higher risk for ischemic events. Accordingly, we explored the risks and benefits of DPI therapy in a generalizable population of patients with concomitant atherosclerotic cardiovascular disease and HF.</div></div><div><h3>Methods</h3><div>The <strong>X</strong>arelto plus <strong>A</strong>cetylsalicylic acid <strong>T</strong>reatment patterns and <strong>O</strong>utcomes in patients with <strong>A</strong>therosclerosis (XATOA) registry is a prospective, multicentre registry of patients with either coronary artery or peripheral artery disease that were given DPI therapy. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke, and the safety outcome was major bleeding. Multivariable logistic regression was performed to assess the association of HF status and ejection fraction (EF) on the outcomes of interest.</div></div><div><h3>Results</h3><div>Of 5532 participants, 4022 (72.7%) had documentation of HF status. Of those 873 (21.5%) had a history of HF (EF &gt; 40%, 461; EF ≤ 40%, 181, EF unknown, 231). Over a median follow-up of 465 days (interquartile range, 372-576), the primary outcome occurred in 4.9% of participants with HF compared with 2.4% in those without HF (adjusted hazard ratio, 1.57; 95% confidence interval, 1.02-2.41). The safety outcome was similar in patients with and without HF (0.9% vs 1.11%; a hazard ratio, 0.7; 95% confidence interval, 0.31-1.67).</div></div><div><h3>Conclusions</h3><div>In a generalizable cohort of patients with atherosclerotic disease and HF, the use of DPI therapy is associated with outcomes similar to those observed in recent randomized controlled clinical trials.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 473-480"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Hannover Postinfarction Ventricular Septal Rupture Score: A New Scoring System Predicting 30-Day Mortality","authors":"Lisa Baustert ,&nbsp;Dietmar Boethig MD ,&nbsp;Adelheid Görler MD ,&nbsp;Christian Kühn MD ,&nbsp;Alexander Weymann MD ,&nbsp;Bastian Schmack MD ,&nbsp;Aron-Frederik Popov MD ,&nbsp;Arjang Ruhparwar MD ,&nbsp;Bettina Wiegmann MD","doi":"10.1016/j.cjco.2024.12.013","DOIUrl":"10.1016/j.cjco.2024.12.013","url":null,"abstract":"<div><h3>Background</h3><div>Because of the increasing importance of quality assurance and individualised patient treatment, EuroSCOREs were analysed for reliability in predicting 30-day mortality in patients with postinfarction ventricular septal rupture (piVSR). To address the specific conditions of patients with piVSR, the Hannover piVSR Score (HpiVSR) was developed.</div></div><div><h3>Methods</h3><div>Between 2001 and 2019, 45 patients with piVSR underwent surgery. Data were collected as necessary for EuroSCORE calculation. Clinically relevant variables were validated for the HpiVSR Score using a nonparsimonious binary logistic regression model. All models were tested for their significant predictive power for 30-day mortality. Their validity was assessed using Hosmer-Lemeshow test and Nagelkerke <em>R</em>². Receiver operating characteristic curve and area under the curve were used to illustrate and quantify score accuracy.</div></div><div><h3>Results</h3><div>The specificity was 77.8% for all EuroSCOREs and 92.6% for the HpiVSR Score, and the sensitivity was in the random range for the EuroSCOREs and 83.3% for the HpiVSR Score. Accordingly, the areas under the curve were 0.676 (95% CI 0.507-0.845) for EuroSCORE II; 0.729 (95% CI 0.581-0.878) and 0.739 (95% CI 0.591-0.886) for the additive and logistic EuroSCORE, respectively; and 0.949 (95% CI 0.891-1.006) for the HpiVSR Score.</div></div><div><h3>Conclusion</h3><div>The HpiVSR Score enables a more reliable and accurate prediction of 30-day mortality than the EuroSCOREs using 7 significant, objective, reliable, and preoperatively determinable variables. Because of the small sample size of the present study and the fact that only internal validation has been performed so far, the weighting of the factors of the HpiVSR Score can be adjusted after studies with larger patient samples.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 456-464"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}